Disclosures & Cautionary Statements

The information contained in this Investor presentation is provided only as informational and is subject to change without notice. The content presented in person, digital, video, written and orally, as well as all other supplemental documents, is for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The information is based on publicly available information, internally developed data as well as third party information from other sources. The Investor presentation of Mycrodose Therapeutics Inc. team, does not claim to contain all the information that may be necessary to fully or accurately evaluate an investment in Mycrodose Therapeutics Inc. Nor is this information to be considered as a recommendation by the Mycrodose Therapeutics, Inc. that any person make an investment in the Mycrodose Therapeutics, Inc.

You should examine the suitability of this type of investment in the context of your own needs, investment objectives and financial capabilities, and make your own independent investigation and decision as to suitability and as to the risk and potential gain involved. Also, you are encouraged to consult with your own accountant, financial consultant, attorney, or other business or tax advisor regarding the risks of the proposed investment. Forward-looking statements are subject to various risks and assumptions when used as projections within this Investor Deck. Certain statements in this presentation constitute forward-looking information. All statements other than statements of historical fact contained in this presentation, including, without limitation, statements regarding Mycrodose Therapeutics, Inc.’s future, strategy, plans, objectives, goals and targets, and any written and verbal projections are forward-looking statements.

Certain statements made during this presentation regarding Psychedelic APIs (Active Pharmaceutical Ingredients) such as Psilocybin, LSD, Ketamine, MDMA, DMT, or any drug mentioned during this presentation have not been evaluated by the Food and Drug Administration, Health Canada, or other similar regulatory authorities, nor has the efficacy of these Psychedelic APIs have been confirmed by approved research. There is no assurance that the APIs can be used to diagnose, treat, cure or prevent any disease or condition and further scientific research and clinical trials are needed.

No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information presented. Mycrodose Therapeutics, Inc. disclaims and excludes all liability for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. Readers should consult with their own professional advisors regarding their particular circumstances.
Mycrodose Therapeutics

- Mission Driven Company
- Core Expertise is Developing Advanced Drug Delivery Products
- Main Indications for our ADD Products is Mental Health & Cognitive Diseases using Psychedelic APIs.
- Additional focus is the treatment for cancer and cancer related conditions with Ketamine.

Mycrodose Technology

- The company’s core products utilizes its IP-protected Sustained Microdose Technology™
- Comprehensive Transdermal Patent Filed
- Core Technologies around 4 Advanced Drug Delivery Products
- R&D focus on Transdermal (Patches, Gels, Topicals) & Oral Mucosa (Lozenge).

Mycrodose Laboratory

- R&D Laboratory in San Diego, CA
- Lab work and clinical supply production follow GLP and GMP regulations.
- Approved by the Attorney General in California, DEA, and FDA for Research of 4 Schedule I Psychedelic APIs including Psilocybin, LSD, MDMA, and DMT.

Mycrodose Investors

- Investors logos and names are mentioned.
The company’s Full-Time Executive Team has over 100 years of combined experience developing patented drug delivery technologies, a successful track-record of working with the FDA and navigating the clinic trial process, and a proven history of core business fundamentals and successful M&A ventures.

**Chad Conner, Chief Executive Officer**
- 20 year entrepreneurial veteran in cannabis wellness, holistic medicine, pharmaceutical, and integrative health treatment clinics.
- Founded and Sold Pure Ratios to 4Front Ventures (FFNTF)
- Successful exit through Canadian Capital Markets.

**Frank Kochinke, PhD, Chief Science Officer**
- 30 years of Pharmaceutical Industry experience in Advanced Drug Delivery Systems
- Specializing in Transdermal, Buccal, and Biodegradable Implant technologies.
- Published over 50 papers and holds 16 patents
- Successful exits one of which sold with his former company, Oculex, for $400MM to Allergan

**Patrick Eckstrom, Chief Operating Officer**
- 15 years of Executive-level experience building & developing successful companies through proven operational efficiencies and data-driven decisions.
- Expert customer acquisition and customer retention professional targeting B2B and B2C channels effectively generating $1MM+ in MRR

**Alex Mond, Chief Financial Officer**
- Experienced CFO in both private and public companies, specializing in financing & M&A growth strategies within the Pharmaceutical & Life Sciences Sector.
- 35 years of experience in Investment Banking and international business; syndicating more than $12 billion in loan structures and financing.
Proven Track-Record

1990-2000's

Transdermal Drug Delivery Systems

2000-2010

Biodegradable Implant

2014-2020

Oral Mucosa / Lozenge

2020 - Present

4 Core Technologies

$400MM Product Exit

$1MM+ MRR

Huge Exit w/ $1MM+ MRR

© Strictly Confidential Not for Public Distribution
The “Peaks & Valleys” Issue Solved!

• Peaks: Waste drug, create adverse reactions
• Valleys: No therapy

Standard Drug Delivery Methods Have Issues

Peaks:
• Wasted Drug (APIs)
• Adverse Reaction
• Harmful Toxicity
• Psychosis or Permanent Mental Health Issues

Valleys:
• Micro Spikes
• Limited Therapeutic Benefit
• Gaps Between Treatments

Essentially all CONVENTIONAL Drug Administration Forms (capsules, tablets, injections, tinctures, etc.), incl. Macro & Micro doses create Peaks & Valleys
# Importance of Advanced Drug Delivery (ADD) ...with Psychedelics API’s

## ADD - Controlled & Sustained Release

### A. ADD products **Control** Input Rate into Blood
- Plasma level controls brain activity (*entropy, receptor occupancy*)
- Brain activity correlated w/Therapeutic Result (*intensity rating*)

### B. ADD products **Sustain** the Input over prolonged periods of time
- Allowing Physician to Titrate dosage over time to get optimal results

## ADD - Benefits

- High safety profile
- Increased Bioavailability
- Less active ingredient
- Better efficacy
- Fewer side effects
- Convenience
- For Children, Adults, and Elderly
We give the Physician the Tool to Control …

Delivery Rate/ Input into blood stream:
Dose/day (mg/d) & Flux (ug/cm2/hr)

Plasma Level
ng/mL

max
min

Entropy
%-Occupancy
Brain Activity
Activity value
fMRI, ECC, MEG

Subjective Feeling
Scale/Questionnaire

Therapeutically
Desired
Response

max
higher
10
min
elevated
1
Core Advanced Drug Delivery Technologies

Mycrodose Technology

Several different Indications
Several Products

LSD

MDMA

Psilocin

Several different Indications
Several Products

Transdermal Patches/Topicals
Oral / Transmucosal Lozenges
Biodegradable Implants
Sustained Release Capsules

Ketamine

DMT

Several different Indications
Several Products

© Strictly Confidential Not for Public Distribution
Filed Patents Applications

TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT - (Filed March 2021):

- Comprehensive claims
- Covers FDA and Consumer Lines of Patches & Topicals
- Strong ownership of transdermal delivery of all psychedelic API’s

Future Patent Pipeline

Mycrodose has 2+ additional strong patents that are expected to be filed by Q4 2021 (Patent Detailed Sensitive & Restricted)
# Company Timeline & Clinical Pipeline

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transdermal Psilocybin Delivery w/different Receptor Occupancy Ratings (OR)</td>
<td>1. Depression/MDD 2. Autism 3. Obesity</td>
</tr>
<tr>
<td>Sustained Release Ketamine Lozenge Transmucosal</td>
<td>1. Oral Inflammation</td>
</tr>
<tr>
<td>Sustained Release Ketamine Lozenge Transmucosal</td>
<td>1. Depression</td>
</tr>
</tbody>
</table>

## Product Timeline

<table>
<thead>
<tr>
<th>Q3 2020 – Q2 2021</th>
<th>Q3 2021</th>
<th>Q4 2021</th>
<th>Q1 2022</th>
<th>Q2 2022</th>
<th>Q3 2022</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Feasibility</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prototyping</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IND Enabling R</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical TD1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical TD2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical TD3</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Product Exit</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© Strictly Confidential Not for Public Distribution
The global market for advanced drug delivery systems will grow from $231 billion in 2020 to $310 billion by 2025. Mycrodose Therapeutics’ core business model and experience is in successfully developing these delivery systems for Psychedelic APIs to treat mental health.
Financials & Projections

2021 Estimate Market Size (US$M)*

*Psilocybin Transdermal Patch

- Obesity: $6,460M
- Autism: $5,300M
- Depression: $2,800M

Mycrodose Therapeutics Market Share (US$M)

Psilocybin Transdermal Patch (3% market capture)

- Obesity: $182M
- Autism: $159M
- Depression: $84M

Liquidity/Exits Possibilities (12+ Months)

- Sell, License, Co-Develop Products Currently in Development to Big Pharma
- Public Offering (RTO/IPO)
- M&A Possibilities of being Acquired by Larger Pharma Company

© Strictly Confidential Not for Public Distribution
*Internal Estimates
Financing Requirements

Investor Relations & Media Requests for Mycrodose Therapeutics Contact:

Patrick Eckstrom: Chief Operating Officer
Work Email: Patrick@MycrodoseThera.com
Office Phone: 1-619-494-1367
Website: www.MycrodoseThera.com

Institutional Investment Partners:
Mycrodose Therapeutics started from a deep personal need to find better solutions for treating mental health. We have a deep desire of improving the fight against the mental health pandemic that impacts all ages, all ethnicities, all genders, and spans the entire globe.